Comprehensive Stock Comparison
Compare Aurinia Pharmaceuticals Inc. (AUPH) vs Kymera Therapeutics, Inc. (KYMR) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AUPH | 20.4% revenue growth vs KYMR's -16.7% |
| Quality / Margins | AUPH | 101.5% net margin vs KYMR's -7.9% |
| Stability / Safety | AUPH | Beta 0.64 vs KYMR's 1.31 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | KYMR | +191.4% vs AUPH's +78.2% |
| Efficiency (ROA) | AUPH | 38.2% ROA vs KYMR's -17.9%, ROIC 16.6% vs -24.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes therapies for autoimmune diseases with unmet medical needs. It generates revenue primarily from sales of LUPKYNIS — its FDA-approved oral treatment for lupus nephritis — with additional income from its collaboration and licensing agreement with Otsuka Pharmaceutical. The company's key advantage is its first-mover position in the oral treatment space for lupus nephritis, a serious kidney complication of systemic lupus erythematosus where treatment options have been limited.
Kymera Therapeutics is a biopharmaceutical company developing targeted protein degraders — small molecules that harness the body's natural protein degradation system to eliminate disease-causing proteins. It generates revenue primarily through strategic partnerships and milestone payments from pharmaceutical collaborators — with potential future revenue from drug sales if clinical candidates succeed. The company's key advantage is its proprietary Pegasus platform for discovering novel protein degraders, which targets previously "undruggable" proteins and creates a pipeline of first-in-class therapies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AUPH leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). KYMR leads in 1 (Total Returns). 1 tied.
Financial Metrics (TTM)
AUPH is the larger business by revenue, generating $283M annually — 7.2x KYMR's $39M. AUPH is the more profitable business, keeping 101.5% of every revenue dollar as net income compared to KYMR's -7.9%. On growth, AUPH holds the edge at +28.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AUPHAurinia Pharmaceu… | KYMRKymera Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $283M | $39M |
| EBITDAEarnings before interest/tax | $105M | -$349M |
| Net IncomeAfter-tax profit | $287M | -$311M |
| Free Cash FlowCash after capex | $135M | -$234M |
| Gross MarginGross profit ÷ Revenue | +88.5% | +100.0% |
| Operating MarginEBIT ÷ Revenue | +37.1% | -8.9% |
| Net MarginNet income ÷ Revenue | +101.5% | -7.9% |
| FCF MarginFCF ÷ Revenue | +47.8% | -6.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +28.8% | -61.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +152.0% | -11.4% |
Valuation Metrics
| Metric | AUPHAurinia Pharmaceu… | KYMRKymera Therapeuti… |
|---|---|---|
| Market CapShares × price | $1.9B | $7.4B |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $7.2B |
| Trailing P/EPrice ÷ TTM EPS | 6.85x | -24.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.87x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 17.82x | — |
| Price / SalesMarket cap ÷ Revenue | 6.62x | 189.51x |
| Price / BookPrice ÷ Book value/share | 3.38x | 4.88x |
| Price / FCFMarket cap ÷ FCF | 13.85x | — |
Profitability & Efficiency
AUPH delivers a 49.4% return on equity — every $100 of shareholder capital generates $49 in annual profit, vs $-20 for KYMR. KYMR carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to AUPH's 0.13x. On the Piotroski fundamental quality scale (0–9), AUPH scores 7/9 vs KYMR's 4/9, reflecting strong financial health.
| Metric | AUPHAurinia Pharmaceu… | KYMRKymera Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | +49.4% | -19.7% |
| ROA (TTM)Return on assets | +38.2% | -17.9% |
| ROICReturn on invested capital | +16.6% | -24.9% |
| ROCEReturn on capital employed | +18.9% | -27.2% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.13x | 0.05x |
| Net DebtTotal debt minus cash | -$5M | -$275M |
| Cash & Equiv.Liquid assets | $80M | $357M |
| Total DebtShort + long-term debt | $75M | $82M |
| Interest CoverageEBIT ÷ Interest expense | — | -1403.21x |
Total Returns (with DRIP)
A $10,000 investment in KYMR five years ago would be worth $18,851 today (with dividends reinvested), compared to $9,786 for AUPH. Over the past 12 months, KYMR leads with a +191.4% total return vs AUPH's +78.2%. The 3-year compound annual growth rate (CAGR) favors KYMR at 42.8% vs AUPH's 15.9% — a key indicator of consistent wealth creation.
| Metric | AUPHAurinia Pharmaceu… | KYMRKymera Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -7.7% | +25.5% |
| 1-Year ReturnPast 12 months | +78.2% | +191.4% |
| 3-Year ReturnCumulative with dividends | +55.9% | +191.1% |
| 5-Year ReturnCumulative with dividends | -2.1% | +88.5% |
| 10-Year ReturnCumulative with dividends | +497.9% | +174.7% |
| CAGR (3Y)Annualised 3-year return | +15.9% | +42.8% |
Risk & Volatility
AUPH is the less volatile stock with a 0.64 beta — it tends to amplify market swings less than KYMR's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KYMR currently trades 88.7% from its 52-week high vs AUPH's 85.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AUPHAurinia Pharmaceu… | KYMRKymera Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.64x | 1.31x |
| 52-Week HighHighest price in past year | $16.54 | $103.00 |
| 52-Week LowLowest price in past year | $6.83 | $19.45 |
| % of 52W HighCurrent price vs 52-week peak | +85.7% | +88.7% |
| RSI (14)Momentum oscillator 0–100 | 37.4 | 77.9 |
| Avg Volume (50D)Average daily shares traded | 782K | 620K |
Analyst Outlook
Wall Street rates AUPH as "Buy" and KYMR as "Buy". Consensus price targets imply 28.4% upside for KYMR (target: $117) vs 9.4% for AUPH (target: $16).
| Metric | AUPHAurinia Pharmaceu… | KYMRKymera Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $15.50 | $117.31 |
| # AnalystsCovering analysts | 14 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.2% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Sep 20 | Feb 26 | Change |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | 100 | 104.68 | +4.7% |
| Kymera Therapeutics… (KYMR) | 93.69 | 227.36 | +142.7% |
Kymera Therapeutics… (KYMR) returned +89% over 5 years vs Aurinia Pharmaceuti… (AUPH)'s -2%. A $10,000 investment in KYMR 5 years ago would be worth $18,851 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | $173000.00 | $283M | +163515.6% |
| Kymera Therapeutics… (KYMR) | $0.00 | $39M | — |
Aurinia Pharmaceuticals Inc.'s revenue grew from $0M (2016) to $283M (2025) — a 127.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | -134.7% | 101.5% | +175.4% |
| Kymera Therapeutics… (KYMR) | -14.1% | -7.9% | +43.6% |
Aurinia Pharmaceuticals Inc.'s net margin went from -135% (2016) to 101% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | -0.66 | 2.07 | +413.6% |
| Kymera Therapeutics… (KYMR) | -0.48 | -3.69 | -668.8% |
Aurinia Pharmaceuticals Inc.'s EPS grew from $-0.66 (2016) to $2.07 (2025).
Chart 5Free Cash Flow — 5 Years
Aurinia Pharmaceuticals Inc. generated $135M FCF in 2025 (+185% vs 2021). Kymera Therapeutics, Inc. generated $-234M FCF in 2025 (-80% vs 2021).
AUPH vs KYMR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AUPH or KYMR a better buy right now?
Aurinia Pharmaceuticals Inc. (AUPH) offers the better valuation at 6.8x trailing P/E (16.9x forward), making it the more compelling value choice. Analysts rate Aurinia Pharmaceuticals Inc. (AUPH) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AUPH or KYMR?
Over the past 5 years, Kymera Therapeutics, Inc. (KYMR) delivered a total return of +88.5%, compared to -2.1% for Aurinia Pharmaceuticals Inc. (AUPH). A $10,000 investment in KYMR five years ago would be worth approximately $19K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AUPH returned +497.9% versus KYMR's +174.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AUPH or KYMR?
By beta (market sensitivity over 5 years), Aurinia Pharmaceuticals Inc. (AUPH) is the lower-risk stock at 0.64β versus Kymera Therapeutics, Inc.'s 1.31β — meaning KYMR is approximately 105% more volatile than AUPH relative to the S&P 500. On balance sheet safety, Kymera Therapeutics, Inc. (KYMR) carries a lower debt/equity ratio of 5% versus 13% for Aurinia Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — AUPH or KYMR?
Aurinia Pharmaceuticals Inc. (AUPH) is the more profitable company, earning 101.5% net margin versus -794.4% for Kymera Therapeutics, Inc. — meaning it keeps 101.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37.1% versus -891.3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is AUPH or KYMR more undervalued right now?
Analyst consensus price targets imply the most upside for KYMR: 28.4% to $117.31.
06Which pays a better dividend — AUPH or KYMR?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AUPH or KYMR better for a retirement portfolio?
For long-horizon retirement investors, Aurinia Pharmaceuticals Inc. (AUPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.64), +497.9% 10Y return). Both have compounded well over 10 years (AUPH: +497.9%, KYMR: +174.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AUPH and KYMR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: AUPH is a small-cap deep-value stock; KYMR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.